TrialArteriosclerosis, thrombosis, and vascular biology2021

Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.

Marja-Riitta Taskinen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.